argenx SE | Investor Presentation Deck | 25 slides

argenx · 2023-11
arc beats above · slides in the middle · loops below · scroll → 2 LOOPS
SETUP TENSION ANALYSIS EVIDENCE RESOLUTION APPENDIX
HOVER FOR DETAILS · CLICK A SLIDE FOR FULLSCREEN · STEP 1
No image bound to this slide. Wire up imgproxy to display the rendered slide JPEG.

Deck intelligence map

3
coverage by narrative range · generated from this deck JSON

Slide inventory

25
every slide · same image gating as the playbook
01
Slide 1
front_matter
03
The slide uses a background image of a sea with a network-like overlay, reinforcing the 'connected' or 'scientific' theme.establish_context
Open slide detailBeat · Problem (Identify pain)Loop · Cost Of Inaction
04
present_solution
Open slide detailBeat · Problem (Identify pain)Loop · Cost Of Inaction
05
The slide highlights the two different delivery methods (IV vs Subcutaneous) for the same underlying treatment.summarize
Open slide detailBeat · Problem (Identify pain)Loop · Cost Of Inaction
06
The slide uses a hub-and-spoke visual arrangement around a central patient image.summarize
Open slide detailBeat · Solution (Provide relief)
07
The slide uses a circular, iterative process diagram to represent the business strategy.present_framework
Open slide detailBeat · Solution (Provide relief)
08
The slide uses a central circular image overlaying four strategic pillars.summarize
Open slide detailBeat · Solution (Provide relief)
09
The slide uses a 3D-like growth chart to illustrate simultaneous expansion strategies.plan_implementation
Open slide detailBeat · Impact & Next Steps
10
The slide uses a chronological progression (Today vs Future) to outline product development strategy.plan_implementation
Open slide detailBeat · Impact & Next Steps
11
The map uses teal dots for general approvals and a purple dot for a specific location (likely US/Canada focus).establish_context
Open slide detailBeat · Impact & Next Steps
12
The slide uses a pyramid structure to represent market size, with larger patient populations at the base.size_opportunity
Open slide detailBeat · Impact & Next Steps
13
The slide uses a patient-centric approach to humanize clinical trial data and innovation progress.illustrate_case
Open slide detailLoop · Why Now
14
The slide outlines a clinical trial protocol timeline.present_framework
Open slide detailLoop · Why Now
15
The slide outlines a clinical trial protocol with a 1-3 week screening phase followed by a 30-week treatment period.plan_implementation
Open slide detailLoop · Why Now
16
The slide uses a split-screen layout to contrast the established MMN proof-of-concept (left) with the future clinical roadmap (right).plan_implementation
17
Includes a biological mechanism diagram on the left and a clinical trial design timeline on the right.plan_implementation
18
The slide uses a hub-and-spoke style network visualization to represent partnerships.establish_context
19
The slide uses a mix of checkmarks for completed items and specific timeframes for future items.plan_implementation
20
The diagram uses a hub-and-spoke layout with the company logo at the center.establish_context
21
The chart uses a horizontal bar format to represent clinical trial progress for multiple indications under three main programs (VYVGART, ARGX-117, ARGX-119).present_solution
22
Clinical trial design schematic showing randomization, screening criteria, and study endpoints.present_framework
23
Clinical trial design diagram showing randomization, treatment arms (Efgartigimod vs Placebo), concomitant OCS usage, and interim analysis point.present_framework
24
The slide outlines a multi-phase clinical trial structure with specific patient cohorts (IMNM, ASyS, DM) and a GO/NO-GO decision point.plan_implementation
25
Clinical trial design diagram showing patient flow from screening through randomization to treatment and follow-up.present_framework